APO-METFORMIN 850 MG
METFORMIN HYDROCHLORIDE : 850 MG · DIN 02229785 · APOTEX INC
Health Canada status: DORMANT
What is APO-METFORMIN?
APO-METFORMIN 850 MG contains METFORMIN HYDROCHLORIDE : 850 MG. It is listed in the Health Canada Drug Product Database under DIN 02229785, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 17-Aug-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is APO-METFORMIN called?
The same molecule, METFORMIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Metformin Sandoz | Latin | Australia, Czechia, Sweden |
| METFORMIN VIATRIS | Latin | Czechia |
| Metformin Accord | Latin | Czechia, Sweden |
| Glucophage | Latin | Czechia, South Africa |
| Metformin Orifarm | Latin | Sweden |
| Metformin Teva | Latin | Czechia, Sweden |
| APX-METFORMIN | Latin | Australia |
| BROTMIN | Latin | Czechia |
| Diaformin Viatris | Latin | Australia |
| Glucophage Xr | Latin | Czechia, South Africa |
| METFORMIN MEDREG | Latin | Czechia |
| METFORMIN MYLAN | Latin | Czechia |
| METFORMIN-WGR | Latin | Australia |
| STADAMET | Latin | Czechia |
| STADAMET NEO | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02229785 |
|---|---|
| Brand name | APO-METFORMIN |
| Generic / active ingredient | METFORMIN HYDROCHLORIDE : 850 MG |
| Manufacturer | APOTEX INC |
| Strength | 850 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BA02 METFORMIN |
| AHFS class | 68:20.04 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 17-Aug-2021 |
| Original market date | 1996-11-20 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02229785 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2229785 |
| Brand name | APO-METFORMIN |
| Active ingredient / INN | METFORMIN HYDROCHLORIDE : 850 MG |
| ATC code | A10BA02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10 |
| AHFS class | 68:20.04 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
Which pack is which?
| Strength on the label | 850 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code A10BA02 METFORMIN. 45 of 122 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-METFORMIN | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494418 |
| AG-METFORMIN | 850 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494442 |
| APO-METFORMIN ER | 1000 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02460653 |
| APO-METFORMIN ER | 500 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02305062 |
| AURO-METFORMIN | 850 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02438283 |
| GLUCOPHAGE | 500 MG | TABLET | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02099233 |
| GLUMETZA | 1000 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02300451 |
| GLUMETZA | 500 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02268493 |
| JAMP METFORMIN | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380196 |
| JAMP METFORMIN | 850 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380218 |
Who else supplies METFORMIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METFORMIN appears in 1377 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does METFORMIN cost around the world?
METFORMIN is listed on 13 national price registers Nexara tracks, across 523 pack listings published on 12 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 6 | 172 | 03 Sep 2026 |
| Australia | ex-manufacturer | 33 | 96 | 08 Sep 2026 |
| Czechia | max producer price (ex-factory) | 19 | 96 | 03 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 14 | 53 | 03 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 13 | 26 | 03 Sep 2026 |
| Romania | max producer price | 19 | 25 | 03 Sep 2026 |
| South Africa | single exit price | 11 | 15 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 14 | 14 | 03 Sep 2026 |
| United Kingdom | hospital | 10 | 10 | 31 Aug 2026 |
| Hungary | producer price (ex-factory) | 4 | 5 | 03 Sep 2026 |
| Luxembourg | reimbursement | 5 | 5 | 05 Sep 2026 |
| United Arab Emirates | public | 3 | 3 | 31 Aug 2026 |
| Bahrain | retail (max) | 3 | 3 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.